APVO442 / Aptevo Therap - LARVOL DELTA

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects (ACCESSWIRE) - "Aptevo Therapeutics Inc...announced additional details about the Company's preclinical bispecific antibody, APVO442, differentiated to target prostate cancer with enhanced precision and minimized safety risk. APVO442 is engineered to address treatment challenges associated with later stage diagnosis with its unique design that enables precise tumor targeting while activating the immune system in a controlled manner. The molecule binds to Prostate-Specific Membrane Antigen (PSMA) on prostate cancer cells where it activates T cells within the tumor and enhances targeted tumor cell killing....Preclinical studies have shown that the molecule readily localizes to solid tumors by avoiding unwanted binding to immune cells circulating in the bloodstream."

Preclinical • Prostate Cancer • Solid Tumor

APVO442 is a distinct PSMA x CD3 targeted bispecific candidate designed to optimize T cell fitness and distribution to solid tumors (AACR 2022) - "These data support the potential for unique clinical combination of APVO442 with immuno-oncology modalities that may support improved benefit in PSMA positive indications such as metastatic castration resistant prostate cancer. APVO442 is undergoing further preclinical in vitro and in vivo characterization in support of the IND-enabling package."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting (Yahoo Finance) - "Aptevo Therapeutics...announced the presentation of preclinical data for APVO442 in a poster session at the American Association for Cancer Research (AACR) Annual Meeting....The presentation...highlights the potential of APVO442 to treat prostate cancer indications such as metastatic castration-resistant prostate cancer with increased benefit and decreased side effects relative to other potential therapeutics in the bispecific category."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urothelial Cancer

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights (Yahoo Finance) - "Business Highlights: Showcased the Company's preclinical assets, APVO442 and APVO603, and their potential to improve efficacy in the treatment of solid tumors and participated in discussions about risk mitigation in cell engager candidates at the Virtual Cell Engager Summit."

Preclinical • Oncology • Solid Tumor

[VIRTUAL] APVO442: A bispecific T cell-engaging candidate utilizing the ADAPTIR-FLEXTMplatform technology with unique properties designed for optimal tumor distribution and cytotoxic response against PSMA-expressing solid tumors (AACR 2021) - "The in vivo activity of APVO442 was comparable to high affinity CD3 engaging comparators with similarly measured PK profiles. Additional in vivo characterization of APVO442 is ongoing and continued pre-clinical studies are planned for 2021."

IO biomarker • Late-breaking abstract • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD4 • CD69 • CD8 • FOLH1 • IL2RA

Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting (Yahoo Finance) - "Aptevo Therapeutics...announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021. The posters will provide preclinical updates on APVO603 and Aptevo's newest pipeline candidate, APVO442."

Preclinical • Oncology • Solid Tumor